Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 + Serplulimab + chemotherapy vs placebo + Serplulimab or Pembrolizumab + chemotherapy in first-line advanced squamous NSCLC
CTR20260205Phase 3Active
- Sponsor
- HyBioPharma
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pimurutamab in Pulmonary squamous cell carcinoma, sponsored by HyBioPharma. Started May 2026; status: active.
02
Drugs
pimurutamab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20260205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260205.